Vicore Pharma, Audiocast with teleconference, 2021

May 4th 2021 15:00 (Europe/Stockholm)
Carl-Johan Dalsgaard, VD Vicore Pharma AB Jessica Shull, Head of Digital Therapeutics Vicore Pharma Hans Jeppsson, CFO, Vicore Pharma John Drakenberg Renander, VD Alex Therapeutics
Health care - Pharmaceuticals & Biotechnology
Small Cap
Audiocast with teleconference
Dial-in number Sweden (Sverige): +46856642705 United Kingdom: +443333009031 United States: +18338230589

Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF.

The agreement with Alex Therapeutics marks the initiation of a new clinical program for Vicore (VP04) – the joint development and commercialization of a clinically validated digital therapeutic (DTx) will provide cognitive behavioral therapy (CBT) for patients suffering from IPF. Under the agreement, Vicore will own all rights to VP04 in exchange for an upfront payment to Alex Therapeutics of 8.1 MSEK (1 MUSD), plus potential milestone payments and royalties on sales.

För mer info klicka här.